ArticleJournal of experimental & clinical cancer research : CR2019

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.

Raghupathy Vengoji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.